4T1 Orthotopic Mouse Model Service for Breast Cancer

The 4T1 orthotopic mouse model stands as one of the most aggressive and clinically relevant syngeneic platforms for studying triple-negative breast cancer progression and spontaneous multi-organ metastasis in an immunocompetent host. At Alfa Cytology, we specialize in building and validating this model to support your preclinical pipeline—delivering reproducible tumor kinetics, quantitative metastasis tracking, and comprehensive endpoint analysis tailored to your compound's mechanism of action.

Overview of 4T1 Orthotopic Mouse Model for Breast Cancer

The 4T1 mammary carcinoma cell line was originally isolated in 1974 by Fred Miller and colleagues from a spontaneously arising mammary tumor in a BALB/cfC3H mouse. Unlike conventional xenografts that require immunodeficient hosts, 4T1 is a syngeneic allograft model transplanted into immunocompetent BALB/c mice, preserving intact innate and adaptive immunity throughout tumor evolution. The cells exhibit a triple-negative phenotype—lacking expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2)—making this model particularly relevant for preclinical studies targeting triple-negative breast cancer, which accounts for over 17% of annual diagnoses worldwide. When implanted orthotopically into the mammary fat pad, 4T1 recapitulates the full malignant arc of human disease: primary tumor formation, local invasion, lymph node dissemination, and spontaneous distant metastasis to lungs, liver, bone, and brain.

Fig 1. EMT6 vs 4T1 in situ model BLI (Week 8), MRI (W1/W2/W3), ex vivo lung chemiluminescence quantitative PCR, lymph node/lung H&E. (Piranlioglu, Raziye, et al., 2019)

A distinctive advantage of the 4T1 system lies in its isogenic sibling lines—67NR, 168FARN, 4TO7, and 66cl4—all derived from the same primary tumor yet arrested at discrete steps of the metastatic cascade. This genetic toolkit enables stepwise dissection of molecular drivers governing intravasation, circulation survival, extravasation, and organ-specific colonization. Furthermore, 4T1 cells are readily engineered to stably express firefly luciferase or fluorescent reporters, permitting non-invasive, longitudinal quantification of tumor burden and micrometastatic seeding via bioluminescence imaging. The model's rapid tumor incidence (approaching 100% within 21–30 days) and predictable metastatic timeline (3–6 weeks post-implantation) make it an exceptionally efficient platform for screening anti-metastatic agents, evaluating immuno-oncology modalities, and interrogating tumor–microenvironment crosstalk in a physiologically faithful context.

Cell Line Information: 4T1

The 4T1 cell line is a 6-thioguanine–resistant subline derived from the parental 410.4 tumor line without mutagenesis screening. It grows as an adherent monolayer with epithelial-like morphology and maintains high tumorigenicity upon orthotopic transplantation. The table below summarizes the key characteristics of the 4T1 cell line commonly used in preclinical breast cancer research.

Our Services

Alfa Cytology operates a dedicated in vivo pharmacology unit where each 4T1 orthotopic study is executed under rigorously controlled conditions—from cell line authentication and mycoplasma screening through to surgical implantation, longitudinal tumor monitoring, and multi-parameter endpoint analysis. Our team leverages bioluminescence imaging, digital caliper measurements, and histopathological validation to generate publication-quality datasets that advance your preclinical development program with speed and scientific rigor.

Workflow of 4T1 Orthotopic Mouse Model Construction

Construction of the 4T1 orthotopic model follows a standardized yet flexible protocol that ensures high tumor take rates and reproducible metastatic progression. The entire process spans cell preparation, surgical implantation, post-operative monitoring, optional primary tumor resection, and longitudinal metastasis assessment. Each phase is conducted under IACUC-approved guidelines with meticulous attention to animal welfare and data integrity.

1. Cell Preparation & Quality Control: 4T1 cells are expanded from authenticated, low-passage stocks and verified free of mycoplasma and viral contaminants. On the day of surgery, cells are harvested with trypsin-EDTA, washed twice in sterile PBS, counted via hemocytometer, and resuspended in HBSS or PBS at the desired concentration—typically 2 × 10⁵ cells/ml for a 50 µl injection volume. Cell viability is confirmed by trypan blue exclusion before proceeding.
2. Animal Preparation: Female BALB/c mice aged 6–8 weeks are acclimatized for at least one week prior to surgery. The surgical site—centered on the 3rd or 4th inguinal mammary gland—is shaved and sterilized with 70% ethanol under isoflurane anesthesia (2% in oxygen, continuous flow).
3. Orthotopic Cell Injection: A 50 µl suspension containing 1 × 10⁴ to 1 × 10⁵ 4T1 cells is drawn into a ½ cc tuberculin syringe fitted with a 27 G needle. The needle is inserted into the mammary fat pad at a shallow angle to deposit cells within the glandular stroma without penetrating the abdominal wall. The injection site is briefly compressed to prevent reflux, and mice are recovered on a heated pad before returning to housing.
4. Primary Tumor Monitoring: Tumor growth is monitored every 2–3 days beginning approximately one week post-implantation. Tumor dimensions are measured with digital calipers, and volume is calculated using the modified ellipsoid formula (length × width² × 0.5). For luciferase-expressing 4T1 lines, bioluminescence imaging is performed after intraperitoneal luciferin injection to quantify tumor burden non-invasively.
5. Optional Primary Tumor Resection: When tumors approach institutional size limits (typically ~1,000 mm³ or ~30 days post-implantation), mice are anesthetized and the primary tumor is excised en bloc with surrounding skin and mammary tissue. This surgical step extends survival by 3–4 weeks, allowing micrometastases to progress into macroscopic lesions and providing an extended therapeutic window for anti-metastatic agent evaluation.
6. Metastasis Assessment & Endpoint Analysis: Following resection, mice are imaged weekly via bioluminescence to track metastatic spread. At study termination, animals are euthanized and organs (lungs, liver, spleen, bones, brain, lymph nodes) are harvested for ex vivo imaging, histopathology, immunohistochemistry, and flow cytometry. Lung metastatic nodules may be quantified by India ink inflation followed by stereomicroscopic counting for orthogonal validation of imaging data.

Fig 2. 4T1 Orthotopic Mouse Model construction workflow.

Case Study-4T1 Orthotopic Mouse Model Development

In a recent preclinical engagement, Alfa Cytology established an orthotopic 4T1 model to evaluate the anti-metastatic potential of a novel small-molecule inhibitor targeting the tumor microenvironment. Following mammary fat pad implantation of luciferase-expressing 4T1 cells, primary tumors were monitored via bioluminescence imaging and resected at day 28 to mimic the clinical scenario of postsurgical residual disease. Treatment groups received the investigational compound or vehicle control beginning one week after tumor removal, with dosing continued for an additional 21 days. Longitudinal imaging revealed differential metastatic burden between cohorts, while terminal histopathology confirmed reduced pulmonary nodule counts and diminished liver micrometastases in the treated group. Flow cytometric analysis of tumor-infiltrating leukocytes further uncovered treatment-induced shifts in myeloid-derived suppressor cell populations, providing mechanistic insight into compound activity within the immunocompetent tumor milieu.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your 4T1 orthotopic breast cancer study means gaining access to a team that treats every model as a bespoke scientific instrument—not a commodity. Our infrastructure, expertise, and quality systems are purpose-built to deliver decision-ready data that withstands regulatory and peer-review scrutiny.

• Authenticated cell stocks with documented STR profiles and routine mycoplasma screening eliminate genetic drift and contamination risks that compromise data integrity.
• Our surgical team has performed hundreds of orthotopic mammary fat pad implantations with >95% tumor take rates and minimal perioperative mortality.
• In-house bioluminescence and fluorescence imaging capabilities enable real-time, quantitative tracking of tumor growth and metastatic burden without interim euthanasia.
• Flexible study designs accommodate primary tumor resection, combination therapy arms, and multi-timepoint sampling to match your specific mechanistic or efficacy objectives.
• Comprehensive endpoint packages include digital pathology, immunohistochemistry, flow cytometry, and cytokine profiling—all processed within our integrated analytical laboratory.
• Dedicated project scientists provide weekly data updates and interim reports, ensuring full transparency and the agility to refine protocols in response to emerging findings.
• All procedures are conducted under IACUC oversight with strict adherence to AAALAC guidelines, generating audit-ready documentation for IND-enabling submissions.

Contact Us

Whether you are advancing a first-in-class immuno-oncology agent or refining the anti-metastatic profile of a lead compound, Alfa Cytology's 4T1 orthotopic model service provides the preclinical rigor your program demands. Reach out to us today to discuss your study parameters, review our standard operating protocols, and receive a customized proposal aligned with your timeline and budget. Our scientific team is ready to transform your therapeutic hypothesis into robust, publication-grade preclinical data.

For research use only. Not intended for any clinical use.